Anixa biosciences announces poster presentation on ovarian cancer car-t clinical trial at the esmo gynaecological cancers congress 2025

San jose, calif. , june 9, 2025 /prnewswire/ -- anixa biosciences, inc. ("anixa" or the "company") (nasdaq: anix), a biotechnology company focused on the treatment and prevention of cancer, today announced that dr. robert wenham, chair of the gynecologic oncology program at moffitt cancer center, and the principal investigator of the phase 1 clinical trial of anixa's ovarian cancer car-t immunotherapy, will present an e-poster at the european society for medical oncology ("esmo") gynaecological cancers congress 2025, to be held on june 19-21, 2025 in vienna, austria.
CAR Ratings Summary
CAR Quant Ranking